CD274 and neoplasm: The findings from the treatment interactions analysis, which encompassed variables such as tumor mutational burden (TMB), programmed death-ligand 1 (PD-L1) expression (classified as high vs. low/medium), and treatment regimen (ipilimumab-nivolumab vs. pembrolizumab), along with their interactions, revealed noteworthy correlations.